Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the systemic levels of beclomethasone 17 monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP HFA with the systemic levels of 17 BMP after administration of orally inhaled BDP HFA in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Pharmaceutical Industries

Criteria

Inclusion Criteria:

• Informed Consent

• Male or female subjects 18-45 years of age

• General good health

Exclusion Criteria:

• History of physical findings of nasal pathology (within 60 days prior to Screening Visit)

• Participation in any investigational drug study 30 days preceding Screening Visit

• History of respiratory infection/disorder with 28 days preceding Screening Visit